| Overview |
| bsm-62019r-rbitc-100ul |
| TAB1 Recombinant Monoclonal Antibody, RBITC Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TAB1 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10454 |
| Q15750 |
| Cytoplasm |
| MAP3K7IP1; TAB1; TAK1 binding protein 1. |
| Key adapter protein that plays an essential role in JNK and NF-kappa-B activation and proinflammatory cytokines production in response to stimulation with TLRs and cytokines.Mechanistically, associates with the catalytic domain of MAP3K7/TAK1 to trigger MAP3K7/TAK1 autophosphorylation leading to its full activation. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz